| 中文名称 |
BML-277 抑制剂 |
| 中文别名 |
2-[4-(4-氯苯氧基)苯基]-1H-苯并咪唑-5-甲酰胺;2-[4-(4-氯苯氧基)苯基]-1H-苯并咪唑-5-羧酰胺;BML-277 抑制剂 |
| 英文名称 |
BML-277 |
| 英文别名 |
2-[4-(4-chlorophenoxy)phenyl]-1H-benzimidazole-6-carboxamide;1H-benzimidazole-5-carboxamide, 2-[4-(4-chlorophenoxy)phenyl]-;2-(4-(4-chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxylic acid amide;2-[4-(4-chlorophenoxy)phenyl]-1H-benzimidazole-5-carboxamide;BML-277;2-(4-(4-CHLOROPHENOXY)PHENYL)-1H-BENZO[D]IMIDAZOLE-5-CARBOXAMIDE;2-[4-(4-chlorophenoxy)phenyl]-3H-benzimidazole-5-carboxamide;Chk2 Inhibitor II;BML277;C 3742;2-[4-(4-Chlorophenoxy)phenyl]-1H-benzimidazole-5-carboxylic acid amide |
| CAS No. |
516480-79-8 |
| 分子式 |
C20H14ClN3O2 |
| 分子量 |
363.80 |
温馨提示：我公司实验室产品会根据市场需求进行更新，产品详情图片仅供参考，以实际收到货物为准。
Biochem/physiol Actions
Chk2 Inhibitor II is a checkpoint kinase 2 inhibitor, which controls the p53 response to DNA breaks induced by radiation, leading to apoptosis. Protection of T-cells from apoptosis implies use as an adjuvant for radiation therapy in cancer.
Chk2 Inhibitor II is a checkpoint kinase 2 inhibitor, which controls the p53 response to DNA breaks induced by radiation, leading to apoptosis. Protection of T-cells from apoptosis implies use as an adjuvant for radiation therapy in cancer. IC50 = 15 nM; Ki = 37 nM. Chk2 Inhibitor II shows 1000-fold greater selectivity for the Chk2 serine/threonine kinase than for the Cdk1/B and CK1 kinases (for which IC50 = 12 μM and 17 μM, respectively). Chk2 Inhibitor II weakly inhibits a panel of 31 other kinases (<25% inhibition at a concentration of 10 μM and prevents apoptosis of human CD4+ and CD8+ T-cells subjected to ionizing radiation (EC50 = 3 μM and 7.6 μM, respectively).
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
| 象形图 |
|
| 警示语 |
|
| Class |
|
| 警告声明 |
|
| UNub |
|
| 危险声明 |
|
| Packing Group |
|
